{"organizations": [], "uuid": "d2cacfb0db27c3f8c7cd6596d7064e63c2d82a3c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/05/pr-newswire-tikcro-technologies-reports-fourth-quarter-and-year-end-2017-results.html", "country": "US", "domain_rank": 767, "title": "Tikcro Technologies Reports Fourth Quarter and Year End 2017 Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-05T16:00:00.000+02:00", "replies_count": 0, "uuid": "d2cacfb0db27c3f8c7cd6596d7064e63c2d82a3c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/05/pr-newswire-tikcro-technologies-reports-fourth-quarter-and-year-end-2017-results.html", "ord_in_thread": 0, "title": "Tikcro Technologies Reports Fourth Quarter and Year End 2017 Results", "locations": [], "entities": {"persons": [{"name": "aviv boim", "sentiment": "none"}, {"name": "tikcro", "sentiment": "none"}], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "tikcro", "sentiment": "none"}], "organizations": [{"name": "tikcro technologies ltd.", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NESS-ZIONA, Israel, March 5, 2018 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the fourth quarter and full year ended December 31, 2017.\nAviv Boim, CEO of Tikcro, commented, \"We continue to promote a full human cytotoxic T lymphocyte-associated antigen 4 (\"CTLA-4\") blocking antibody, currently in small animal efficacy models for cancer treatment. This antibody shows strong results in cancer inhibition animal models. Further, we plan to pursue additional pre-clinical work through 2018 to support regulatory applications for the commencement of clinical trials.\"\nThe CTLA-4 blocking antibody approved market is for the treatment of melanoma. The market size for CTLA-4 blocking antibodies exceeds $1 billion per annum. Several pharma companies, including Tikcro, are pursuing new CTLA-4 antibodies to broaden its clinical scope and to reduce its immune related adverse effects.\nFinancial Results for the Fourth Quarter Ended December 31, 2017\nNet loss for the fourth quarter of 2017 was $277,000, or $0.03 per diluted share, compared to a net loss of $340,000, or $0.03 per diluted share, for the same period last year.\nFinancial Results for the Year Ended December 31, 2017\nNet loss for the year ended December 31, 2017 was $1,251,000, or $0.13 per diluted share, compared to a net loss of $1,280,000, or $0.13 per diluted share, for the year ended December 31, 2016.\nAs of December 31, 2017, the Company had a cash and cash equivalents balance of $6.6 million.\nAbout Tikcro Technologies\nTikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro's website at www.tikcro.com .\nSafe Harbor Statement\nCertain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the risks related to early stage biotechnology projects, including, but not limited to, obtaining required licenses at reasonable commercial terms, the development, testing, regulatory approval and commercialization of our proposed products, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. We undertake no duty to update any forward-looking information.\nTikcro Technologies Ltd.\nCondensed Balance Sheets\n(US dollars in thousands)\nDecember 31,\n2017\nUnaudited\nDecember 31,\n2016\nAudited\nAssets\nCurrent assets\nCash and cash equivalents\n$\n6,562\n$\n7,507\nReceivables and other financial asset\n21\n89\nTotal current assets\n6,583\n7,596\nProperty and equipment, net\n125\n136\nTotal assets\n$\n6,708\n$\n7,732\nLiabilities and Shareholders' Equity\nCurrent liabilities\nOther current liabilities\n$\n309\n$\n237\nShareholders' equity\n6,399\n7,495\nTotal liabilities and shareholders' equity\n$\n6,708\n$\n7,732\nTikcro Technologies Ltd.\nStatements of Operations\n(US dollars in thousands, except per share data)\nThree Months Ended\nDecember 31\nYear Ended\nDecember 31\n2017\n2016\n2017\n2016\nResearch and development\nexpenses\n$\n145\n$\n163\n$\n678\n$\n601\nGeneral and administrative\nexpenses, net\n171\n176\n618\n676\nTotal operating expenses\n316\n339\n1,296\n1,277\nOperating loss\n(316)\n(339)\n(1,296)\n(1,277)\nFinancial income (expenses), net\n39\n(1)\n45\n(3)\nNet loss\n$\n(277)\n$\n(340)\n$\n(1,251)\n$\n(1,280)\nBasic and diluted net loss per share\n$\n(0.03)\n$\n(0.03)\n$\n(0.13)\n$\n(0.13)\nWeighted average number of\nshares used computing basic and\ndiluted loss per share\n9,879\n9,879\n9,879\n9,879\nView original content: http://www.prnewswire.com/news-releases/tikcro-technologies-reports-fourth-quarter-and-year-end-2017-results-300607680.html\nSOURCE Tikcro Technologies Ltd.", "external_links": ["http://www.prnewswire.com/news-releases/tikcro-technologies-reports-fourth-quarter-and-year-end-2017-results-300607680.html", "http://www.tikcro.com/"], "published": "2018-03-05T16:00:00.000+02:00", "crawled": "2018-03-05T17:17:59.000+02:00", "highlightTitle": ""}